ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
She was Group Chief Marketing Officer at CKA Birla Group in her last role
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated
